PDSB

1.65

5.71% -0.10

Dopo l'orario di chiusura: 1.76 0.11 +6.67%

Pds Biotechnology Corporation (PDSB)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$1.75

Aprire:

$1.75

Volume 24 ore:

573.15K

Relative Volume:

1.33

Capitalizzazione di mercato:

$61.73M

Reddito:

Utile/perdita netta:

$-40.56M

Rapporto P/E:

-1.0185

EPS:

-1.62

Flusso di cassa netto:

$-35.28M

1 W Prestazione:

-10.33%

1M Prestazione:

-18.52%

6M Prestazione:

-35.29%

1 anno Prestazione:

-66.05%

Intervallo 1D:

$1.63

$1.8083

Intervallo di 1 settimana:

$1.63

$2.045

Portata 52W:

$1.53

$6.68

Pds Biotechnology Corporation Stock (PDSB) Company Profile

Nome

Pds Biotechnology Corporation

Settore

Healthcare (1176)

Industria

Biotechnology (673)

Telefono

800-208-3343

Indirizzo

303A COLLEGE ROAD EAST, PRINCETON

Dipendente

Cinguettio

@pdsbiotech

Prossima data di guadagno

2024-11-12

Ultimi documenti SEC

PDSB's Discussions on Twitter

Confronta PDSB con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PDSB Pds Biotechnology Corporation	1.65	61.73M	0	-40.56M	-35.28M	-1.17
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2022-11-01	Iniziato	B. Riley Securities	Buy
2021-06-28	Iniziato	Cantor Fitzgerald	Overweight
2020-11-10	Aggiornamento	H.C. Wainwright	Neutral → Buy
2020-05-27	Iniziato	Alliance Global Partners	Buy
2020-03-09	Iniziato	Noble Capital Markets	Outperform
2019-10-24	Iniziato	Chardan Capital Markets	Buy

Mostra tutto

Pds Biotechnology Corporation Borsa (PDSB) Ultime notizie

Dec 18, 2024

PDS Biotechnology (NASDAQ:PDSB) Receives "Buy" Rating from HC Wainwright - MarketBeat

Dec 18, 2024

Dec 06, 2024

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Dec 06, 2024

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Dec 06, 2024

PDS Biotech Grants Stock Options to New Clinical Employee Under Inducement Plan - StockTitan

Dec 06, 2024

Dec 03, 2024

PDSBPDS Biotechnology Corporation Latest Stock News & Market Updates - StockTitan

Dec 03, 2024

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET - The Manila Times

Dec 03, 2024

PDS Biotech Announces Expert Panel on HPV16 Cancer Treatment Phase 3 Trial - StockTitan

Dec 03, 2024

Dec 02, 2024

BioGene Therapeutics Welcomes Stephen Glover to Its Board of Directors - Newsfile

Dec 02, 2024

Nov 28, 2024

Research Analysts Issue Forecasts for PDSB FY2024 Earnings - Defense World

Nov 28, 2024

Nov 27, 2024

FY2024 EPS Estimate for PDS Biotechnology Lowered by Analyst - MarketBeat

Nov 27, 2024

Nov 20, 2024

Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround - Yahoo Finance

Nov 20, 2024

PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2024 Earnings Call Transcript - MSN

Nov 20, 2024

Nov 18, 2024

PDS Biotechnology’s (PDSB) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 18, 2024

Versamune HPV Could Bolster Long-Term Efficacy With Pembrolizumab in HPV16-Driven HNSCC - OncLive

Nov 18, 2024

Nov 16, 2024

PDS Biotechnology's (PDSB) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Nov 16, 2024

PDS Biotechnology to Present at H.C. Wainwright Bioconnect Virtual Conference - StockTitan

Nov 16, 2024

Nov 15, 2024

PDS Biotechnology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 15, 2024